OIS Podcast | Ophthalmology's leading Podcast

OIS Podcast | Ophthalmology's leading Podcast


What’s New in Ocular Surface Disease?

August 04, 2023

Two recent drug approvals changed the game for ocular surface disease: Xdemvy (lotilaner ophthalmic solution) 0.25 percent (Tarsus Pharmaceuticals) for Demodex blepharitis, and Miebo (perfluorohexyloctane ophthalmic solution) from Bausch + Lomb and Novali